SGCB and systemic sclerosis: Pharmacological modulation of sGC with riociguat has been shown to exert a trend towards clinical efficacy in patients with early dcSSc and a high risk of skin fibrosis progression.28 In a randomised, double-blind, placebo-controlled, Phase IIb study (RISE-SSc), riociguat was well tolerated and showed potential efficacy signals in secondary and exploratory analyses.